Zynerba Pharmaceuticals Analysis
| ZYNEDelisted Stock | USD 1.30 0.04 3.17% |
Zynerba Pharmaceuticals is overvalued with Real Value of 0.92 and Hype Value of 1.3. The main objective of Zynerba Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Zynerba Pharmaceuticals is worth, separate from its market price. There are two main types of Zynerba Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Zynerba Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Zynerba Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Zynerba Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Zynerba Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Zynerba Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Zynerba Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Zynerba |
Zynerba Stock Analysis Notes
The company has Price to Book (P/B) ratio of 0.54. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zynerba Pharmaceuticals recorded a loss per share of 0.8. The entity had not issued any dividends in recent years. Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more information please call Armando MBA at 484 581 7505 or visit https://www.zynerba.com.Zynerba Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Zynerba Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Zynerba Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Zynerba Pharmaceuticals is not yet fully synchronised with the market data | |
| Zynerba Pharmaceuticals may become a speculative penny stock | |
| Zynerba Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zynerba Pharmaceuticals currently holds about 62.49 M in cash with (23.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Zynerba Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Zynerba Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zynerba Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of November 2023 Upcoming Quarterly Report | View | |
| 26th of March 2024 Next Financial Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Zynerba Pharmaceuticals Thematic Classifications
In addition to having Zynerba Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | MarijuanaEntities with exposure to distribution of Marijuana |
Zynerba Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 70.12 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zynerba Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Zynerba Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Zynerba Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zynerba Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zynerba Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zynerba Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kenneth Moch over six months ago Disposition pursuant to a tender of shares in a change of control transaction by Kenneth Moch of Zynerba Pharmaceuticals | ||
Brian Rosenberger over six months ago Acquisition by Brian Rosenberger of 22200 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 | ||
Kenneth Moch over six months ago Acquisition by Kenneth Moch of 47824 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 | ||
Parker Albert P over a year ago Sale by Parker Albert P of 3173 shares of Zynerba Pharmaceuticals | ||
Parker Albert P over a year ago Acquisition by Parker Albert P of 18864 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 | ||
Parker Albert P over a year ago Acquisition by Parker Albert P of 17631 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 |
Zynerba Pharmaceuticals Predictive Daily Indicators
Zynerba Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zynerba Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Zynerba Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Zynerba Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zynerba shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Zynerba Pharmaceuticals. By using and applying Zynerba Stock analysis, traders can create a robust methodology for identifying Zynerba entry and exit points for their positions.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Zynerba Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |